Malaria accounts for an enormous burden of disease globally, with Plasmodium falciparum
accounting for the majority of malaria, and P. vivax being a second important cause …

That humans in endemic areas become immune to malaria offers encouragement to the
idea of developing protective vaccines. However natural immunity is relatively inefficient …

Early data emerging from the first phase 3 trial of a malaria vaccine are raising hopes that a
licensed vaccine will soon be available for use in endemic countries, but given the relatively …

Malaria is a leading cause of mortality and morbidity globally, and effective vaccines are
urgently needed. Malaria vaccine approaches can be broadly grouped as pre‐erythrocytic …

Background Antigen-specific antibody-mediated immune responses play an important role
in natural protection against clinical malaria, but conflicting estimates of this association …

The development of a malaria vaccine seems to be a definite possibility despite the fact that
even individuals with a life time of endemic exposure do not develop sterile immunity. An …

The C-terminal 19-kDa fragment of Plasmodium falciparum merozoite surface protein-1
(MSP-1 19) is a target of protective Abs against blood-stage infection and a leading …

Over the last 30 years, evidence has been gathered suggesting that merozoite surface
protein 1 (MSP1) is a target of protective immunity against malaria. In a variety of …

Although the malaria parasite was discovered more than 120 years ago, it is only during the
past 20 years, following the cloning of malaria genes, that we have been able to think …

Antibodies to the C terminus of the Plasmodium falciparum merozoite surface protein,
PfMSP-119, may inhibit merozoite invasion or block the effects of inhibitory antibodies. Here …